U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C29H31N7O3
Molecular Weight 525.6026
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELPERCATINIB

SMILES

CC(C)(COc1cc(-c2ccc(nc2)N3CC4CC(C3)N4Cc5ccc(nc5)OC)c6c(C#N)cnn6c1)O

InChI

InChIKey=XIIOFHFUYBLOLW-UHFFFAOYSA-N
InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C29H31N7O3
Molecular Weight 525.6026
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Jun 26 00:11:16 UTC 2021
Edited
by admin
on Sat Jun 26 00:11:16 UTC 2021
Record UNII
CEGM9YBNGD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SELPERCATINIB
INN   USAN  
Official Name English
LOXO-292
Code English
SELPERCATINIB [USAN]
USAN  
Common Name English
6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO(3.1.1)HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO(1,5-A)PYRIDINE-3-CARBONITRILE
Systematic Name English
RET INHIBITOR LOXO-292
Common Name English
RETEVMO
Brand Name English
LY-3527723
Code English
SELPERCATINIB [WHO-DD]
Common Name English
LY3527723
Code English
PYRAZOLO(1,5-A)PYRIDINE-3-CARBONITRILE, 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXY-3-PYRIDINYL)METHYL)-3,6-DIAZABICYCLO(3.1.1)HEPT-3-YL)-3-PYRIDINYL)-
Systematic Name English
SELPERCATINIB [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 675218
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
EU-Orphan Drug EU/3/18/2071
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
FDA ORPHAN DRUG 653118
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
FDA ORPHAN DRUG 652318
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
Code System Code Type Description
PUBCHEM
134436906
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
PRIMARY
NCI_THESAURUS
C134987
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
PRIMARY
DRUG BANK
DB15685
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
PRIMARY
INN
10967
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
PRIMARY
LACTMED
Selpercatinib
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
PRIMARY
FDA UNII
CEGM9YBNGD
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
PRIMARY
CAS
2152628-33-4
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
PRIMARY
RXCUI
2370147
Created by admin on Sat Jun 26 00:11:16 UTC 2021 , Edited by admin on Sat Jun 26 00:11:16 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
at higher concentrations that were still clinically achievable
BINDER->LIGAND
Protein binding of selpercatinib is 97% in vitro and is independent of concentration.
BINDING
TRANSPORTER -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
at higher concentrations that were still clinically achievable
TARGET -> INHIBITOR
TARGET -> INHIBITOR
EXCRETED UNCHANGED
FECAL
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
at higher concentrations that were still clinically achievable
EXCRETED UNCHANGED
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
blood- to-plasma ratio PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

IN THE HEALTHY SUBJECTS